Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | How will CAR-T cells help us cure Ph+ ALL?

Peter Bader • 25 Oct 2019
COSTEM 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Peter Bader, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, outlines the mechanisms by which CAR-T cells will help us cure Philidelphia positive acute lymphoblastic leukemia (Ph+ ALL) in adults. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Peter Bader

1:13
Transplantation in an evolving therapy landscape
Peter Bader • 26 Oct 2019
2:14
Mesenchymal stromal cells in the treatment of acute GVHD
Peter Bader • 25 Oct 2019
4:13
Prof. Bader’s highlights from EBMT 2019
Peter Bader • 10 Apr 2019
0:57
The aims of the EBMT Paediatric Disease Working Party
Peter Bader • 9 Sep 2016

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals